The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Recent advances in CAR-T therapy for MDS
David Sallman, MD, Moffit Cancer Center, Tampa, FL, outlines recent advances in the field of CAR-T therapy for myelodysplastic syndromes (MDS), highlighting some of the challenges in this space. Dr Sallman explains that many of the antigens targeted in acute myeloid leukemia (AML), including CD33, CD123, and CLL-1, are also expressed in patients with higher-risk MDS. There is currently little data on the efficacy of these CAR-Ts, but a recent ongoing study has suggested that CD33-targeted CAR-Ts appear promising. According to Dr Sallman, CAR-Ts developed for the treatment of AML should also be evaluated in the MDS setting, and novel CAR-Ts targeting multiple antigens should be designed. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Incyte: Speakers Bureau; AbbVie: Membership on an entity’s Board of Directors or advisory committees; Aprea: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Bristol-Myers Squibb: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Agios: Membership on an entity’s Board of Directors or advisory committees; Intellia: Membership on an entity’s Board of Directors or advisory committees; Kite: Membership on an entity’s Board of Directors or advisory committees; Magenta: Consultancy; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Syndax: Membership on an entity’s Board of Directors or advisory committees; Shattuck Labs: Membership on an entity’s Board of Directors or advisory committees; Takeda: Consultancy.
